ASC930

ASC Therapeutics · Phase 2 active Biologic

ASC930 is a small molecule that targets the [insert target here, if known].

At a glance

Generic name	ASC930
Sponsor	ASC Therapeutics
Modality	Biologic
Phase	Phase 2

Mechanism of action

Unfortunately, I do not have information on the specific mechanism of ASC930.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ASC930 CI brief — competitive landscape report
ASC930 updates RSS · CI watch RSS
ASC Therapeutics portfolio CI